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Abstract 
There is a rise in the popularity of arthroscopic procedures in orthopedics. However, the 
majority of cell based bone tissue engineered constructs rely on solid pre-formed 
scaffolding materials, which require large incisions and extensive dissections for 
placement at the defect site. Thus, they are not suitable for minimally invasive techniques. 
The aim of this study was to develop a clinically relevant, easily moldable, bone tissue 
engineered construct (TEC), amenable to minimally invasive techniques, using human 
mesenchymal stromal cells (hMSC) and calcium phosphate micro particles in 
combination with an in-situ forming platelet rich plasma (PRP) gel obtained from human 
platelets.  Most conventional TECs rely on seeding and culturing single cell suspensions 
of hMSCs on scaffolds. However, for generating TECs amenable to the minimally 
invasive approach, it was essential to aggregate the hMSCs in vitro prior to seeding them 
on the scaffolds as unaggregated MSCs did not generate any bone. 24 hours of in vitro 
aggregation was determined to be optimal for maintaining cell viability in vitro and bone 
formation in vivo. Moreover, no statistically significant difference was observed in the 
amount of bone formed when the TECs were implanted via an open approach or a 
minimally invasive route. TECs generated using MSCs from three different human 
donors generated new bone through the minimally invasive route in a reproducible 
manner, suggesting that these TECs could be a viable alternative to pre-formed scaffolds 
employed through an open surgery for treating bone defects.  
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1. Introduction 
The repair of bone non-unions and defects remains a significant clinical problem. Though 
autologous bone grafts are the preferred treatment option, their availability is limited and 
their use is often associated with donor site morbidity [1, 2]. Allografts can help 
overcome some of the disadvantages of autografts. However, the scarcity of suitable 
donors and possible risks of immunogenic reactions and disease transmissions limit their 
routine use [3]. An alternative option available to the surgeons is the use of tissue 
engineered bone grafts.  Conventionally, for bone tissue engineering approaches, the 
MSCs harvested from the patient, are expanded in culture and combined with a pre-
formed scaffold to generate a tissue engineered construct (TEC) [4]. Such tissue 
engineered constructs (TECs) have been shown to form bone convincingly in ectopic and 
orthotopic locations in many animal models as well as in a few human studies [5-8].  
  
However, it is often difficult to fit a pre-formed scaffold into a defect with a complex 
geometric shape as can be the case following trauma or tumor resections. Further, pre-
formed scaffolds are not amenable to arthroscopic techniques. An open operation is often 
required to place the graft at the defect site. Such open surgeries are often associated with 
significant manipulation of the soft tissues with consequent risk of infections and longer 
intra- operative times[9]. This is of special concern in cases of staged surgical 
interventions, where multiple invasive surgeries may be associated with increased patient 
morbidity and negative aesthetic effects. Thus, development of tissue engineered bone 
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grafts which can be implanted through minimally invasive procedures can  result in 
immediate clinical benefits, both in terms of convenience for the surgeon and faster 
recovery time for the patient [10]. 
 
Several injectable gels and cements such as calcium phosphate cements (CPC), polymeric 
gels, agarose, hyaluronate, cellulose, fibrinogen based gels, collagen and pluronic acid 
have been suggested as an injectable biomaterials for the purpose of bone tissue 
engineering [11-13]. While the CPCs provide good biomechanical stability, the 
exothermic reactions associated with their setting process prove to be a deterrent in 
combining them with cells. One of the approaches reported to overcome this drawback 
involves the use of self-dissolving alginate beads which serve as a protective capsule for 
the cells during setting of the injectable cements. Though an interesting approach, the 
results have not yet been verified in vivo [14, 15]. Agarose gels, on the other hand, are a 
suitable delivery system for cartilage tissue engineering but do not support blood vessel 
ingrowth thus making them inadequate for bone tissue engineering. The degradation 
products of pluronic acid are cytotoxic whilst the curing of hyaluronic acid from solution 
to a gel is difficult making it unsuitable for routine clinical use. Gels from synthetic 
polymers often result in inflammatory reactions [12]. Collagen, alginate and fibrinogen 
based gels are biocompatible and thus suitable for use with cells. However, of these three 
in situ gel forming compounds, fibrinogen based gels offer distinct advantages as it gels 
at body  temperature, can be prepared from the patient’s own plasma, and has proven 
biocompatibility and biodegradability [15-17] . Trombi et al. further demonstrated in 
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 5 
vitro that fibrin based gels supported hMSC proliferation and differentiation and could be 
used as a delivery vehicle for hMSCs [18].  
 
The use of fibrinogen as an osteoconductive material and a medium for compacting grafts 
has been well reported [19]. They have been used in conjunction with other biomaterials 
such as coral or hydroxyapatite to heal bone defects [20, 21]. It has been demonstrated 
that fibrin glue can be used as a carrier for calvarial osteoprogenitor cells to repair critical 
sized osseous facial defects [22] and for periosteal cells to induce heterotropic 
osteogenesis in rat experiments [23]. It has also been reported that fibrin glue together 
with periosteum derived osteoprogenitor cells can heal segmental bone defects in rabbits 
[9]. An  indirect evidence of the benefits of the osteoinducitivity of fibrin and plasma 
based products was provided by Rochet et al. who used blood clotted  around ceramics 
and MSCs to develop a cohesive mouldable TEC with osteogenic properties [24].    
 
To test the possibility of employing fibrin based gels for injectable purposes, Yamada et 
al. used a combination of fibrin gel with rat MSCs and β-TCP scaffolds to generate bone 
at an ectopic site [25]. In a follow up study, they replaced the fibrin gel with platelet rich 
plasma (PRP) gel (PRP gel is a fibrin gel enriched with the growth factors released from 
platelets) with in vitro expanded canine MSCs for treating mandibular defects in dogs 
[26]. Recently a study using hMSCs derived from adipose tissue was used to develop an 
injectable TEC for bone regeneration [27]. In all the above mentioned studies, the PRP 
gel functioned as the scaffolding material as well as the delivery vehicle. To add further 
osteoconductive and osteoinductive properties to the resulting graft and to improve its 
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mechanical stability,  Mankani et al. used a fibrin based gel in combination with a single 
cell suspension of hMSCs and HA/TCP particles [10]. This formulation when injected 
into ectopic and orthotopic sites in mice generated bone, thus providing a proof of 
principle on the possible use of ceramics and hMSCs with fibrinogen as an injectable 
formulation for generating bone in vivo. [10]. However, the fibrin gel was of mouse 
origin and the HA /TCP particle size used in this study was in the range of 0.5 to 1 mm. 
Studies demonstrating the possibility of employing smaller particle sizes for bone tissue 
engineering applications have been reported [24, 28]. This can potentially facilitate the 
delivery of the TECs via a minimally invasive approach. 
  
It is well known that the in vitro culture conditions of MSCs can influence their in vivo 
performance. In that context, it has recently been reported by multiple researchers that 
culturing MSCs as aggregates can improve their osteogenic and chondrogenic 
differentiation capacities [29-31] . Within our laboratory, we observed that greater 
amounts of bone were obtained in vivo when a single cell suspension of hMSCs 
conventionally used in bone tissue engineered constructs was replaced by hMSC 
aggregates (manuscript submitted).  
 
The aim of the present study is to combine hMSC aggregates, micro ceramic particles 
and human platelet derived  PRP gel into a safe (due to the autologous origins of the cells 
and gel), relatively low cost, easily obtainable TEC with in vivo osteogenic potential that 
can be delivered at the defect site using minimally invasive techniques. 
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2. Materials and Methods:  
2.1 Cell culture 
Bone marrow aspirates (5-20 ml) were obtained from healthy donors during hip 
replacement surgery with written informed consent. Alternatively cryopreserved vials of 
hMSCs were purchased (Lonza group ltd). When isolated from fresh marrow aspirates, 
the aspirates were resuspended using 20G needles and plated at a density of 5×10
5
/ cm
2 
and cultured in basic medium supplemented with 1 ng/mL basic fibroblast growth factor 
(bFGF, Instruchemie, The Netherlands). This medium is henceforth referred to as 
proliferation medium. Basic medium was made of a-minimal essential medium (a-MEM, 
Life Technologies), 10% foetal bovine serum (FBS, Cambrex), 0.2 mM ascorbic acid 
(Asap, Life Technologies), 2 mM L-glutamine (Life Technologies), 100 U/mL penicillin 
(Life Technologies) and 10 mg/mL streptomycin (Life Technologies). Cells were grown 
at 37°C in a humid atmosphere with 5% CO2. Medium was refreshed twice a week and 
on reaching near confluence, cells were trypsinised and cryopreserved till further use. At 
the start of the experiments, the cryovials were expanded further in the proliferation 
medium until numbers sufficient for experiments were obtained.  
  
 2.2 Generation of Cell aggregates 
400 μm diameter wells with a depth of 200 μm were patterned on poly(dimethylsiloxane) 
(PDMS) stamps using etched silicon wafers (fig 1A) according to established protocols 
[32]. After sterilising the PDMS stamps for 10 minutes in 70% ethanol, they were placed 
in the wells of a standard 6 well plate and completely covered with 3% agarose solution 
(Ultra-pure agarose, Invitrogen). Upon solidification, the chips were demoulded and the 
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 8 
agarose templates were placed in a non-tissue culture treated 12 well plate. After wetting 
the chips with medium, a concentrated suspension (1ml) of 1.5 million cells was 
uniformly dispersed over the wells on each agarose chip. Agarose chips were then 
centrifuged briefly at 1500 rpm to facilitate the cells to settle down on the chips. For 
culturing on the chips, the medium used (termed Exp. Medium) was serum free and 
composed of Dulbecco’s Modified Eagle’s Medium supplemented with 10-7M 
dexamethasone, 50 mg/ml ascorbic acid (Asap, Life Technologies), 40 mg/ml proline 
(Sigma-Aldrich), 100 mg/ml sodium pyruvate, 50 mg/ml ITS 1 Premix (Becton-
Dickinson). 1.5 ml of the Exp. Medium was added to each chip. Cells spontaneously 
compacted to form aggregates within 24 hours. For the study comparing the viability of 
the cells after 1 day, 1 week and 2 weeks of in vitro culture, the aggregates were left in 
the agarose chips for 1 day, 1 week and 2 weeks respectively. Medium was changed 
every alternate day during culture in the agarose chips 
 
2.3 Platelet rich plasma (PRP) gel 
After written informed consent, venous blood was withdrawn from healthy blood donors 
and passed through an apharesis unit at the Institut für Klinische Transfusionsmedizin, 
Braunschweig. Platelets were isolated and immediately frozen at -80 °C. At the time of 
the experiment, the bag was thawed at 37 °C. This freeze thaw cycle resulted in lysis of 
the platelets with subsequent release of the growth factors and formation of the platelet 
lysate. 235 µl 1 M calcium chloride solution was added per 10 ml of platelet lysate and 
gently mixed on a shaker at 37 °C degrees for approximately 10 minutes. This resulted in 
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 9 
the separation of the platelet lysate into a gel like component and a clear liquid. The clear 
liquid was the source of the thrombin component which when added at a 1: 1 ratio at  
37 °C to the rest of the platelet lysate (fibrin source), activated the clotting pathway, 
thereby resulting in the formation of a PRP gel in 10-12 seconds 
 
2.4 Calcium phosphate micro ceramics 
Biphasic calcium phosphate (BCP) micro ceramics of sizes 53-63 µm and sintered at 
1150 °C were provided by Xpand Biotechnology BV, The Netherlands. The particles 
contain 20±5% beta-tricalcium phosphate and 80±5% hydroxyapatite. The particles were 
autoclaved at 121 ºC for 30 minutes before use. 
 
2.5 Generation of constructs for in vivo implantation 
In the minimally invasive approach, the cell aggregates were flushed out of the 
microchips and immediately mixed with approximately 25 µg of BCP micro ceramics 
and fibrin and thrombin components (1:1 ratio) of the PRP gel just prior to implantation. 
The mix was then directly introduced into the defect through a small hole measuring 
approximately 1mm and just enough to hold the tip of the pipette. The pipette tips were 
pre cooled and the cell ceramic constructs were also kept on ice to slow the gelling time. 
The contents were very slowly introduced into the defect and the edges of the pocket 
were held up to contain the spreading in the subcutaneous space and to ensure that the 
contents did not leak out from the sides. The injected material gelled within 20-30 
seconds after injection. The pocket was then closed using 5-0 vicryl sutures. As a control, 
we implanted in the same animals, with an open 2 mm incision, the construct generated 
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 10 
after the cells were mixed with scaffolds, fibrin and thrombin and then left to gel at 37 °C 
for 15 minutes prior to implantation. 
 
2.5 Cell viability assays 
The viability of the cell aggregates within the constructs generated using cell aggregates, 
micro ceramics and platelet gel, and deposited using a pipette tip at the bottom of a 6 well 
plate was checked using an MTT assay. The constructs were incubated with 1 ml Exp. 
Medium and 20 µl MTT solution (5 mg/ml; Gibco) per well for 2 hours at 37 ºC in a 5% 
CO2 atmosphere incubator. Images were captured using a phase contrast microscope and 
MATRIX Vision SRGB 32 Bit software.  
 
The viability of cells in the aggregates cultured for 1 day, 1 week and 2 weeks within the 
micro wells of the agarose chips were checked using a live dead assay (Invitrogen, 
Carlsbad, CA). The two components of the kit, ethidium homodimer 1 and calcein were 
mixed in a ratio of 4:1 and diluted in PBS as per the protocol recommended by the 
manufacturers. The constructs were incubated in the resulting mixture for 30 minutes in 
the dark. The fluorescence from the calcein dye was observed using a filter for the FITC 
488 dye while the fluorescence for ethidium homodimer was observed using filters for 
Texas red dye. The images were captured using a colour camera (Nikon FDX-35) and 
QCapture software.  
 
2.6 Gene expression analysis 
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Cells aggregated in the microwells for 1 day, 1 week or 2 weeks were washed briefly 
with PBS and lysed using Trizol reagent (Invitrogen, Carlsbad, CA). The samples were 
stored for at least 12 hours at -80 
ο
C for RNA isolation. After chloroform addition and 
phase separation by centrifugation, the aqueous phase containing the RNA was collected, 
mixed with equal volume of 75% ethanol and loaded onto the RNA binding column of a 
Nucleospin RNA II kit (Bioke). Subsequent steps were in accordance with the 
manufacturer’s protocol. The RNA yields were determined by spectrophotometry using 
the Nanodrop1000 (ND-1000 spectrophotometer, Isogen Life Science). Subsequently 
cDNA was synthesized using iScript (BioRad) according to the manufacturer’s 
recommendations. 3 μl of undiluted cDNA was used for subsequent analysis. For 
quantitative PCR, a master mix, containing distilled water, forward primer, reverse 
primer (Sigma Genosys), BSA and SYBR green I mix (Invitrogen) was prepared. Real-
time qPCR was performed, for the osteogenic genes, on a MyIQ single colour real-time 
PCR detection system (BioRad). Gene expression was normalized to the expression of 
Beta-2 microglobulin (B2M) gene. My IQ data was analysed using iQ
tm
5 optical system 
software (Biorad). Ct values were normalized to the B2M housekeeping gene and 
comparative ∆Ct method (Ct control - Ct sample) was used to calculate the fold 
inductions. Primer sequences are listed in Table 1. 
 
2.7 In vivo studies 
An immune deficient mouse model was used for assessing the bone forming capacity of 
the hMSCs. TECs were introduced into their subcutaneous pockets either by injection or 
by an open approach. Ten immune deficient male mice (Hsd-cpb: NMRI-nu, Harlan) 
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were used for each experiment. The mice were anesthetized by inhalation of isofluorane 
and carbon dioxide. For the open approach, a 2 mm incision was made on the dorsal 
aspect of each mouse while for the injectable approach, a hole was made using an 18 
gauge needle and then enlarged to approximately 1mm in order to fit the pipette tip. The 
openings in either case were closed using a vicryl 5-0 suture. The constructs were left in 
the mice for 6 weeks at the end of which the mice were euthanized using carbon 
monoxide and the samples were explanted. The size of the explanted samples in both 
cases averaged around 2 mm. All the experiments were approved by the local animal 
experimental committee. 
 
2.8 Bone Quantification 
The explanted samples were fixed in 4% paraformaldehyde (Merck) and embedded in 
methacrylate for sectioning. Approximately 300 µm-thick, undecalcified sections were 
processed on a histological diamond saw (Leica saw microtome cutting system). At least 
4 sections were cut per sample. Each section was stained with basic fuchsin and 
methylene blue to visualize new bone formation. The newly formed mineralized bone 
stains red with basic fuchsin, the unmineralized osteoid stains light pink while all other 
cellular material stains blue with methylene blue. The ceramic material remains black and 
unstained by both the dyes. For quantitative histomorphometric analysis, three randomly 
selected slides were first scanned using a PathScan Enabler IV histology slide scanner. 
Mature and immature bone was manually pseudocoloured green while the scaffold 
material was pseudocoloured red using Photoshop CS2 (Adobe Systems). The total 
scaffold area was defined as the area of interest. A custom-made Matlab script was used 
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to measure the amount of bone within the area of interest. These values were then 
averaged and expressed as a percentage of the total scaffold area occupied by newly 
deposited bone in each condition.  
 
2.9 Statistics 
All in vitro experiments were performed in triplicate. Statistical analysis was performed 
using One-way Anova followed by Tukey’s multiple comparison test (P<0.05) when 
more than 2 groups were compared. When the statistical analysis was performed between 
2 groups, a Student’s paired t-test was used. As in the case of Anova, a p value less than 
0.05 was considered as significant. 
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3. Results 
3.1 Characterization of cell aggregates 
To generate cell aggregates, 1.5 million MSCs were dispersed uniformly over the micro 
wells on each agarose chip. The agarose chip was then centrifuged briefly to permit the 
MSCs to settle within the chips. At this stage, the MSCs occupied the entire microwell, 
which measured 400 µm in diameter and 100 µm in depth (fig 1B). However within 24 
hours, the cell aggregates condensed and on an average measured 220 µm in diameter 
(fig 1C). The average size of the aggregates after flushing was approximately 175 µm (fig 
1D). In order to determine if the loss in size was associated with a decrease in cell 
viability, MTT assays were performed on the aggregates before and after flushing from 
the agarose chips. The results of the assay suggested that majority of the cells were viable 
even after flushing out of the chips (fig 1E). Next, cell aggregates, micro ceramic 
particles and the PRP gel were combined within a pipette tip before being ejected out as a 
TEC. To investigate if the shear force experienced by the cell-ceramic-PRP construct, 
during passage through the pipette tips, alters the integrity of the cell aggregates, the 
ejected TECs were visualized under a light microscope. Cell aggregates were seen 
interspersed with the micro ceramic particles indicating that the majority of the 
aggregates remained intact even after passing through the pipette tips (fig 1F). MTT 
staining of the aggregates within the resulting TECS suggested that passage through the 
pipette tip did not affect their viability (fig 1G).  
 
3.2 In vitro evaluation of the possibility to engineer TECs of different shapes 
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One of the major drawbacks of using pre-formed scaffolds is the difficulty associated 
with adapting it to complex geometric shapes as can be the case following trauma or 
tumor resections. In such cases, the surgeon needs to either fabricate ex vivo complicated 
scaffold geometries or carve the defect site. In order to test the possibility of adapting   
our injectable TEC into defects of varying shapes and sizes, cell aggregates were 
combined with micro ceramics and PRP gel and injected into moulds having rectangular, 
cross and triangular shapes. The PRP gel guided the cells and ceramics to fit the contours 
of the different morphologies before gelling, thereby resulting in TECs with varying 
shapes and sizes (fig 2). Our results thus suggest that our PRP gel based injectable TEC 
can be used to engineer in vivo bone of different sizes and shapes. 
 
3.3 Optimization of the in vitro culture time of cell aggregates   
In order to maximize cell-cell interactions in vitro, we investigated the possibility of a 
longer in vitro culture time of the cell aggregates on the agarose chips by assessing its 
influence on cell viability and osteogenic gene expression. MSCs were seeded and 
cultured on the agarose chips for 1 day, 1 week and 2 weeks. In all cases, the medium 
was refreshed every alternate day. Cell viability was performed using a live/dead staining 
kit.  We observed a steady increase in red fluorescence (suggestive of dead cells) with an 
increase in the in vitro culture duration. This suggested that cell viability is compromised 
upon extended culture (fig 3 A, B, C). On qPCR analysis of the expression of a panel of 
commonly used osteogenic genes, we observed that there was no significant difference in 
the expression of either BMP-2 or osteocalcin at the different time points. However, ALP 
gene expression was highest at one week with a significant decrease at the two week time 
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point. Collagen 1 expression was the highest following one day in culture but thereafter 
decreased significantly. Thus, we concluded that prolonged in vitro culturing did not 
enhance the overall osteogenic gene expression (fig 3D). To determine if the in vivo bone 
formation paralleled our in vitro findings, 1 day, 1 week and 2 week old aggregates 
generated using MSCs from the same donor that was used for the in vitro study, were 
implanted subcutaneously for 6 weeks in a nude mouse model. Previously in our lab, on 
culturing unaggregated MSCs with ceramics and PRP gel for 2 weeks in vitro, we 
obtained bone in vivo, although the amounts were significantly lower compared to 
constructs employing aggregated cells (manuscript submitted). To determine whether 
unaggregated MSCs could also generate bone via the minimally invasive approach, we 
combined 1.5 million unaggregated cells with micro ceramics and PRP gel and 
introduced these TECs in parallel with the TECs employing aggregated MSCs cultured 
for 24 hours, 1 week and 2 weeks into the subcutaneous pocket of nude mice. For a fairer 
comparison, the MSCs for both aggregated and unaggregated TECs were from the same 
donor. After 6 weeks of in vivo implantations, the amount of bone was determined 
histomorphometrically in all the TECs. In the unaggregated group, no bone formation 
was observed. The average amounts of bone generated for the total scaffold area varied 
from 6.6, 7.1 and 4.4% for 1 day old aggregates, 1 week old aggregates and 2 week old 
aggregates respectively (fig 3E). Statistical evaluation indicated that the differences 
between these three groups were not significant. These results suggest that whilst 
aggregation is essential for bone formation, a longer in vitro culture time is not beneficial 
for in vivo bone formation.  
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3.5 Evaluation of in vivo bone formation using MSCs from multiple donors 
TECs were generated using MSC aggregates from 3 different donors. The aggregates 
from all the three donors were cultured in vitro for 24 hours prior to combining with 
micro ceramics and PRP gel.  These resulting TECs were introduced into the 
subcutaneous pocket on the dorsum of 10 nude mice via a small opening just wide 
enough to hold the pipette tip. Histological analysis of constructs after 6 weeks 
demonstrated abundant bone formation within the TECs generated using MSCs from all 
the three donors (fig 4A). More specifically on average, 10.03%, 3.1% and 5.6% of the 
total scaffold area was occupied with newly formed bone in the constructs using 
commercially obtained MSCs, D236 and D 240 respectively (fig 4B). This data suggest 
that our TECs introduced into the defect via a minimally invasive route can reliably 
generate bone in vivo.  
 
3.6 Comparison of the injectable system with the open approach in terms of in vivo 
bone formation 
Conventionally tissue engineered constructs are introduced into a defect site via an open 
incision. Our results indicate that in our system, a minimally invasive approach also 
results in new bone formation in vivo. To investigate if there are significant differences in 
the amounts of bone obtained when the constructs are gelled ex vivo at 37 ºC for 15 
minutes and then inserted via an open incision of around 3 mm, or introduced directly 
into the subcutaneous space of the animal using an opening, big enough to just fit the 
pipette tip and allowed to gel in vivo, we implanted both groups in parallel within the 
same immune-deficient mouse. The study was performed with cells from two human 
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MSC donors (donor 236 and donor 240). In the open approach, the constructs comprising 
the MSC aggregates, micro ceramic particles and PRP gel were generated in vitro on 6 
well plates prior to introducing them into the subcutaneous pocket via a 2 mm incision. In 
the minimally invasive approach, the components of the construct were directly 
introduced into the subcutaneous pocket via a small hole, just big enough to fit the pipette 
tip. On histological evaluation of the two types of samples after 6 weeks, the constructs 
employing cells from donor 236 had on an average 2.9% and 3.1% of the scaffold area 
filled with newly formed bone in the case of the open and injectable approach 
respectively.  In the case of constructs employing cells from Donor 240, on average 5.4% 
of the scaffold area was covered with bone in the open approach versus 4.8% for the 
injectable approach. In both the donors, the differences were not statistically significant, 
(fig 5) indicating that in our system, the minimally invasive approach is a viable 
alternative to the open approach for the purpose of bone tissue engineering. 
 
Discussion 
Injectable bone TECs  that are self-setting in situ and compatible with  the use of MSCs 
can bring significant benefits in several clinical situations, such as mandibular atrophy, 
scaphoid non-unions, spinal disease and craniofacial defects where endoscopic efforts at 
placing conventional bone grafts are already under investigation [33, 34].  In this study 
we developed a TEC suitable for clinical use and amenable to minimally invasive 
approaches by combining human platelet rich plasma (PRP) derived gel, hMSC 
aggregates and micro ceramic particles. We verified the bone forming capacity of the 
TEC using MSCs from multiple donors.  The MSCs used in this study are of human 
 Page 18 of 35
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
En
gi
ne
er
in
g 
ne
w
 b
on
e 
vi
a 
a 
m
in
im
al
ly
 in
va
siv
e 
ro
ut
e 
us
in
g 
hu
m
an
 b
on
e 
m
ar
ro
w
 d
er
iv
ed
 st
ro
m
al
 c
el
l a
gg
re
ga
te
s, 
m
ic
ro
 c
er
am
ic
 p
ar
tic
le
s a
nd
 h
um
an
 p
la
te
le
t r
ic
h 
pl
as
m
a 
ge
l (
do
i: 1
0.1
08
9/t
en
.T
EA
.20
12
.01
04
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
19 
 19 
origin and the micro ceramics are composed of calcium phosphate compounds that are 
commonly used for orthopedic and dental applications [35-37]. The gelling of the PRP 
gel, in addition to being temperature dependent only occurs after the two components, i.e. 
fibrin and thrombin are mixed together giving the surgeon time and flexibility during the 
surgical procedure.  
 
Tisseel® (Baxter Biosciences, USA) is a commercially available fibrin thrombin based 
sealant that is already approved for clinical use as an adhesive sealant in controlling 
bleeding during surgical procedures [38] . However, the commercially available product, 
unlike that used in this study, is not suitable for tissue engineering applications as the 
high crosslinking density of the fibrin network prevents cell migration within the 
construct [39, 40]. Moreover, the PRP gel used in our current study can be an autologous 
preparation, which can be obtained easily in large quantities, at no extra cost [26] . 
Because of its autologous origins, there are no risks or concerns about disease 
transmission and immunogenic reactions as is the case for allogeneic or xenogeneic 
preparations. Furthermore, unlike the commercially available fibrin glue, the PRP gel is 
derived by activating the release of the native concentration of fibrin within the platelets 
with calcium chloride and thrombin. During the activation of the platelets, a myriad of 
growth factors are released which can potentially enhance bone regeneration and 
vascularization of the construct [41, 42]. 
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A study by Yamada et al. involved the use of a similar autologously derived fibrin 
thrombin gel  in conjunction with canine MSCs for repair of critical sized defects in dogs 
[26]. In this study, the gel in addition to being the delivery vehicle also doubled up as the 
scaffolding material. According to studies reported in literature, a pre-formed solid 
matrix helps with improved retention of cells at the defect site, provides the cells with a 
substrate for bone deposition, acts as filler at the defect site and in many cases, the 
osteoconductive and osteoinductive properties of the scaffold promote faster bone healing 
[18-21].  In fact, we have preliminary results which indicate that the calcium phosphate 
ceramics are necessary to generate bone in our system (data not shown).  
 
A study by Mankani et al. described the use of single cell suspension of hMSCs in 
combination with 0.5-1 mm HA/TCP particles and a mouse fibrinogen and thrombin 
mixture to generate bone in vivo [10]. Our study differed from this study with respect to 
the use of fibrin thrombin gel of human origin and smaller ceramics which aided the 
delivery of the construct into the defect site. Reports in literature suggest that the use of 
micro particles in place of bigger granules increases the surface area available for cell 
attachments and calcium release, both of which can influence in vivo bone formation [43].  
The micro particles can also easily adapt to the contour of the defect without 
compromising the use of the minimally invasive delivery route for the graft placement. 
Finally, as the gel is very soft, the ceramics help to increase the mechanical strength of 
the tissue engineered graft. It can be argued that use of even smaller sized particles can 
further aid the placement of constructs via the minimally invasive approach. According to 
literature evidence, at least in case of HA and TCP particles, 44 µm represents the lowest 
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threshold below which bone marrow derived hMSC-ceramic combinations do not yield 
any bone in subcutaneous locations in nude mice at the two time points tested, i.e. 4 
weeks and 10 weeks. However, whilst this provides an indication, it would be interesting 
to confirm the validity of these findings using particles of different sizes within our 
system [43, 44]. 
 
A salient feature of our study was the use of cell aggregates instead of single cells. We 
observed in the past that in vitro aggregation of the cells prior to in vivo administration, 
significantly improved their performance. Within this study, we observed no bone 
formation when unaggregated cells from the same donor were combined with the 
ceramics and gel and implanted in vivo. These results are in accordance with studies from 
other groups that have reported the beneficial effects of cell aggregation on the 
expression of osteogenic genes [29-31].  It is believed that the behavior of the cells within 
the aggregate can be influenced by the improved integrin specific signaling as a result of 
improved cellular cross-talk within the aggregate [45, 46]. In addition to cell-cell 
signaling, culturing cells as aggregates also improves the interaction of the cells with the 
extracellular matrix (ECM) which in addition to functioning as an adhesive substrate also 
acts as a reservoir of growth factors which play a role in maintaining the differentiation 
potential of the cells [47]. Surprisingly, our results indicate that although the initial 
aggregation was beneficial for in vivo bone formation, neither the expression of the 
osteogenic genes nor the amount of bone obtained rose proportionately to an increase in 
the in vitro culture duration of the cell aggregates.  One of the possible explanations was 
the increase cell death within the aggregates over time. This can be improved by either 
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generating smaller aggregates or through the use of dynamic culturing techniques which 
will ensure a better nutrient supply to the cells in the core of the aggregates. 
 
 In conclusion, we describe here a clinically applicable system using human MSCs for the 
generation of tissue engineered constructs for delivery via a minimally invasive route. 
Future studies aimed at scaling up the size of the implants, implantations at orthotopic 
sites in immunocompetent animals and investigations into the mechanical properties of 
the newly deposited bone in the minimally invasive approach compared to the 
conventional surgically placed implants can all prove beneficial in clinical translation of 
this technique.  Possibilities to replace the need for aggregation of expanded MSCs with 
aggregation of the mononuclear fraction obtained directly from a fresh bone marrow or 
fat tissue may be of interest to further streamline the technique for clinical applications. 
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Figure 1. Characterization of cell aggregates.  
(A) PDMS stamps etched on silicon wafers (B) Cells uniformly seeded on the agarose 
chips generated using the PDMS templates (C) Within 24 hours, the cells compacted to 
form cell aggregates averaging 220 µm in diameter (D) The aggregates retained their 
shape after flushing out of the chips. However, the average size of the aggregates after 
flushing was 175 µm (E) MTT staining confirmed that majority of the cells within the 
aggregates remained viable after flushing out of the chips. The cell aggregates were then 
mixed with ceramic micro particles and PRP gel, were passed through a pipette tip and 
released on the bottom of a 6 well plate as a tissue engineered construct (TEC). (F) The 
cells persisted as aggregates even after passage through the pipette tip. (G) and remained 
viable as confirmed by the MTT staining of the TECs.  
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Fig 2. In vitro evaluation of the possibility to engineer TECs of different shapes 
TECs generated by combining PRP gel, cell aggregates and micro ceramic particles were 
then placed within rectangular, cross shaped and triangular moulds. The TECs adapted to 
the shape of the mould. This suggested that the TECs developed with our system could be 
used to engineer bone of different shapes and sizes. 
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 Fig 3. Effect of prolonged in vitro culturing of cell aggregates on the cell viability 
and osteogenic gene expression.  
1.5 million cells were seeded on each agarose chips and cultured for 1 day, 1 week or 2 
weeks in vitro. The medium was refreshed every alternate day. At the end of (A)1 day 
(B)1 week (C) and 2 weeks, the viability of the cells within the aggregates was analyzed 
using a live dead assay. An increase in the number of red fluorescent dots in aggregates 
cultured for longer periods in vitro indicated that an increase in the period of in vitro 
culturing was associated with a decrease in cell viability. (D) Expression of a panel of 
osteogenic genes was compared between the 1 day, 1 week and 2 week samples. (E) In 
vivo evaluation of the bone forming capacity of the TECs generated using 1 day, 1 week 
or 2 week old aggregates, demonstrated no significant difference in the amount of bone 
formed between these different constructs. However constructs generated using 
unaggregated MSCs from the same donor did not result in any bone in vivo. Results were 
analysed using one way Anova. *P<0.05, **P<0.005. Scale bars represent 100 µm. 
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Figure 4. Evaluation of the in vivo bone forming capacity of injectable TECs using 
multiple donors 
TECs were generated using PRP gel and micro ceramic particles combined with 1 day 
old MSC aggregates from 3 different human donors.  (A) On histological staining with 
methylene blue and basic fuschin after 6 weeks of in vivo implantation, constructs 
generated using all three donors demonstrated large areas of mature bone (b) and osteoid 
(o). The mature bone tissue stained red with basic fuschin and showed presence of bone 
lining cells (indicated by black arrow) and embedded osteocytes (indicated by white 
arrow). The osteoid stained a lighter pink due to the unmineralized nature of the matrix. 
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(B) Graphical representation of the amount of bone formed by the TECS generated using 
MSCs from the three different donors.  
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Fig 5. Comparison of the conventional open approach for introducing constructs 
into a defect with the minimally invasive approach.  
Cell aggregates mixed with micro ceramic particles and fibrin thrombin gel were either 
generated ex vivo and introduced into the nude mice through an open incision or directly 
delivered into the subcutaneous pocket through a pipette tip. Both sets of constructs were 
implanted in parallel in the same animals. The study was repeated with 2 separate donors 
(D 236 and D 240). In both the donors tested, no significant difference was observed in 
the amount of bone obtained using the open incision approach versus the minimally 
invasive approach of construct delivery via the pipette tip.  
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